Alpha-0261
Phase 1Small molecule
Alpha-0261 is one of 9 small molecule programs targeting Chronic Spontaneous Urticaria (CSU). It is currently in Phase 1.
2
Indications
3
Total Trials
2
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Ulcerative Colitis (UC)
#DrugCompanyPhaseTrials
1Rinvoq
AbbVieApproved
Omvoh
Eli LillyApproved
Vancocin
HHikma Pharmaceuticals LLC
Phase 2
Ponvory
VVanda Pharmaceuticals
Phase 3
AC-101
AAccro Bioscience (Suzhou) Limited
Phase 2
Alinia
RRomark Laboratories L.C.
Preclinical
Alpha-0261
AAlphaMol Science Ltd. (Shanghai)
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ulcerative Colitis (UC)1 trial
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Alpha-0261 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis (UC)
Not yet recruiting·TThe First Affiliated Hospital of Anhui Medical University·Phase 1·NCT07744646·10 enrolled
Chronic Spontaneous Urticaria (CSU)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alpha-0261. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAlphaMol Science Ltd. (Shanghai)